Streetbeat News

Stock Prices

AAPL

Apple's stock surged by 2% following the release of iOS 17 and the announcement of the iPhone 15. The new iOS features, including Live Voicemail, have been well received, but concerns about battery life and device overheating have been raised. The stock price is currently fluctuating between $171 and $198, indicating a consolidation phase. The upcoming release of the iPhone 15 adds an element of intrigue, with investors eagerly awaiting its impact on the stock price.

Portfolio Pulse from Zaheer Anwari

September 20, 2023 | 4:25 pm

CCLD

CareCloud has provided a financial and operational update and reaffirmed its FY23 revenue guidance. This has led to an increase in the company's share price.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2023 | 4:22 pm

AAP

AZO

ORLY

AutoZone, Inc. (NYSE:AZO) reported fiscal fourth quarter earnings and sales that exceeded expectations due to soaring international demand and improved margins. However, domestic commercial growth was lower than expected, causing shares to drop. The company faces competition from Advance Auto Parts Inc (NYSE:AAP) and O'Reilly Automotive Inc (NASDAQ:ORLY). AutoZone's revenue for the quarter was $5.69 billion, a 6.4% YoY increase, and net income was $864.8 million or $46.46 per share, a 6.8% rise. However, domestic sales fell short of expectations, increasing only 3.9% to $1.49 billion. The company's new CEO, Bill Hackney, is expected to address the disappointing U.S. growth and expand the commercial business.

Portfolio Pulse from Upwallstreet

September 20, 2023 | 4:22 pm

GRRR

Gorilla Technology Group has announced a $25 million registered direct offering of convertible preferred stock, leading to a decrease in its share price.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2023 | 4:19 pm

AMGN

A significant bearish stance has been taken on Amgen (NASDAQ:AMGN) by a large investor, as indicated by unusual options activity. The overall sentiment of these big-money traders is split between 31% bullish and 68% bearish. The whales have been targeting a price range from $210.0 to $280.0 for Amgen over the last 3 months. The price of AMGN is up 2.45% at $270.79. Truist Securities downgraded its action to Hold with a price target of $260, Argus Research maintained their Buy rating with a price target of $280, and HSBC downgraded its action to Buy with a price target of $320.

Portfolio Pulse from Benzinga Insights

September 20, 2023 | 4:16 pm

LULU

Investor Business Daily SwingTrader has reportedly purchased stock in Lululemon Athletica.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2023 | 4:14 pm

GPRE

Green Plains Partners has recently combined with an activist-targeted ethanol fuel company, making the latter more attractive to buyers and facilitating asset divestment. This has resulted in a rise in the company's share prices.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2023 | 4:13 pm

SPY

The U.S. government is facing a potential shutdown due to budget negotiations deadlock in Congress. The White House warns of potential damage to the economy and national security. Goldman Sachs predicts a temporary shutdown is increasingly likely, which could reduce quarterly annualized growth by around 0.2 percentage points for each week it persists. Historically, financial markets have not shown significant reactions during government shutdowns, with the S&P 500 recording above-average returns in the year following a shutdown.

Portfolio Pulse from Piero Cingari

September 20, 2023 | 4:13 pm

CATC

FRTX

GIS

ICCM

SCS

SEEL

SPRY

U.S. stocks traded mixed with the Nasdaq Composite turning lower. General Mills Inc reported better-than-expected earnings for its first quarter. Steelcase Inc. reported better-than-expected results for its second quarter. Shares of Cambridge Bancorp surged after the company announced a merger with Eastern Bankshares. Fresh Tracks Therapeutics shares were up after the company announced a plan of liquidation and dissolution. Seelos Therapeutics shares dropped after its SLS-002 Phase II study did not meet the pre-defined primary endpoint. ARS Pharmaceuticals shares were down after the FDA issued a Complete Response Letter regarding its New Drug Application. IceCure Medical shares fell after the FDA denied its De Novo Classification request for breast cancer.

Portfolio Pulse from Lisa Levin

September 20, 2023 | 4:09 pm

EVAX

Evaxion Biotech has announced a collaboration with Afrigen Biologics to develop a mRNA vaccine against Gonorrhea. This news has led to a rise in Evaxion's stock prices.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2023 | 4:05 pm